These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 30266036)

  • 1. ABT-199 (Venetoclax), a BH3-mimetic Bcl-2 inhibitor, does not cause Ca
    Jakubowska MA; Kerkhofs M; Martines C; Efremov DG; Gerasimenko JV; Gerasimenko OV; Petersen OH; Bultynck G; Vervliet T; Ferdek PE
    Br J Pharmacol; 2019 Nov; 176(22):4402-4415. PubMed ID: 30266036
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The selective Bcl-2 inhibitor venetoclax, a BH3 mimetic, does not dysregulate intracellular Ca
    Vervloessem T; Ivanova H; Luyten T; Parys JB; Bultynck G
    Biochim Biophys Acta Mol Cell Res; 2017 Jun; 1864(6):968-976. PubMed ID: 27913204
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BH3 mimetic-elicited Ca
    Ferdek PE; Jakubowska MA; Nicolaou P; Gerasimenko JV; Gerasimenko OV; Petersen OH
    Cell Death Dis; 2017 Mar; 8(3):e2640. PubMed ID: 28252652
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of elevated anti-apoptotic MCL-1 and BCL-2 on the development and treatment of MLL-AF9 AML in mice.
    Anstee NS; Bilardi RA; Ng AP; Xu Z; Robati M; Vandenberg CJ; Cory S
    Cell Death Differ; 2019 Jul; 26(7):1316-1331. PubMed ID: 30470795
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bcl-2 phosphorylation confers resistance on chronic lymphocytic leukaemia cells to the BH3 mimetics ABT-737, ABT-263 and ABT-199 by impeding direct binding.
    Song T; Chai G; Liu Y; Yu X; Wang Z; Zhang Z
    Br J Pharmacol; 2016 Feb; 173(3):471-83. PubMed ID: 26493374
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ABT-199, a new Bcl-2-specific BH3 mimetic, has in vivo efficacy against aggressive Myc-driven mouse lymphomas without provoking thrombocytopenia.
    Vandenberg CJ; Cory S
    Blood; 2013 Mar; 121(12):2285-8. PubMed ID: 23341542
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DLBCL Cells with Acquired Resistance to Venetoclax Are Not Sensitized to BIRD-2 But Can Be Resensitized to Venetoclax through Bcl-XL Inhibition.
    Kerkhofs M; Vervloessem T; Stopa KB; Smith VM; Vogler M; Bultynck G
    Biomolecules; 2020 Jul; 10(7):. PubMed ID: 32708132
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selective Bcl-2 inhibition to treat chronic lymphocytic leukemia and non-Hodgkin lymphoma.
    Ng SY; Davids MS
    Clin Adv Hematol Oncol; 2014 Apr; 12(4):224-9. PubMed ID: 25003352
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BH3 Inhibitor Sensitivity and Bcl-2 Dependence in Primary Acute Lymphoblastic Leukemia Cells.
    Alford SE; Kothari A; Loeff FC; Eichhorn JM; Sakurikar N; Goselink HM; Saylors RL; Jedema I; Falkenburg JH; Chambers TC
    Cancer Res; 2015 Apr; 75(7):1366-75. PubMed ID: 25649768
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antagonism of Bcl-XL is necessary for synergy between carboplatin and BH3 mimetics in ovarian cancer cells.
    Abed MN; Abdullah MI; Richardson A
    J Ovarian Res; 2016 Apr; 9():25. PubMed ID: 27080533
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of BH3-mimetics on Human and Mouse Blood Leukocytes: A Comparative Study.
    Rohner L; Reinhart R; Iype J; Bachmann S; Kaufmann T; Fux M
    Sci Rep; 2020 Jan; 10(1):222. PubMed ID: 31937836
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Both leukaemic and normal peripheral B lymphoid cells are highly sensitive to the selective pharmacological inhibition of prosurvival Bcl-2 with ABT-199.
    Khaw SL; Mérino D; Anderson MA; Glaser SP; Bouillet P; Roberts AW; Huang DC
    Leukemia; 2014 Jun; 28(6):1207-15. PubMed ID: 24402163
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Allosteric modulation of sigma receptors by BH3 mimetics ABT-737, ABT-263 (Navitoclax) and ABT-199 (Venetoclax).
    Lever JR; Fergason-Cantrell EA
    Pharmacol Res; 2019 Apr; 142():87-100. PubMed ID: 30721730
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BH3 mimetics: status of the field and new developments.
    Billard C
    Mol Cancer Ther; 2013 Sep; 12(9):1691-700. PubMed ID: 23974697
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predicting effective pro-apoptotic anti-leukaemic drug combinations using co-operative dynamic BH3 profiling.
    Grundy M; Seedhouse C; Jones T; Elmi L; Hall M; Graham A; Russell N; Pallis M
    PLoS One; 2018; 13(1):e0190682. PubMed ID: 29298347
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BH3-Mimetic Drugs: Blazing the Trail for New Cancer Medicines.
    Merino D; Kelly GL; Lessene G; Wei AH; Roberts AW; Strasser A
    Cancer Cell; 2018 Dec; 34(6):879-891. PubMed ID: 30537511
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Co-targeting of Bcl-2 and mTOR pathway triggers synergistic apoptosis in BH3 mimetics resistant acute lymphoblastic leukemia.
    Iacovelli S; Ricciardi MR; Allegretti M; Mirabilii S; Licchetta R; Bergamo P; Rinaldo C; Zeuner A; Foà R; Milella M; McCubrey JA; Martelli AM; Tafuri A
    Oncotarget; 2015 Oct; 6(31):32089-103. PubMed ID: 26392332
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The first MCL-1-selective BH3 mimetics have therapeutic potential for chronic lymphocytic leukemia.
    Besbes S; Pocard M; Mirshahi M; Billard C
    Crit Rev Oncol Hematol; 2016 Apr; 100():32-6. PubMed ID: 26899021
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BCL-2 selective inhibitor ABT-199 primes rhabdomyosarcoma cells to histone deacetylase inhibitor-induced apoptosis.
    Heinicke U; Haydn T; Kehr S; Vogler M; Fulda S
    Oncogene; 2018 Sep; 37(39):5325-5339. PubMed ID: 29858601
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting intermediary metabolism enhances the efficacy of BH3 mimetic therapy in hematologic malignancies.
    Al-Zebeeby A; Vogler M; Milani M; Richards C; Alotibi A; Greaves G; Dyer MJS; Cohen GM; Varadarajan S
    Haematologica; 2019 May; 104(5):1016-1025. PubMed ID: 30467206
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.